On August 12, 2026, RA Capital Management, L.P., a significant shareholder and director of Septerna, Inc. (NASDAQ: SEPN), filed a Form 4 with the SEC reporting the sale of 1,493,000 shares of Septerna common stock for a total consideration of $63,452,500. The shares were sold at $42.50 each, split equally between two of RA Capital’s affiliated funds: 746,500 shares held indirectly by the RA Capital Healthcare Fund, L.P. and 746,500 shares held indirectly by the RA Capital Nexus Fund III, L.P. Following the disposition, the Healthcare Fund retained an indirect holding of 4,777,415 shares, while the Nexus Fund III retained 725,443 shares of Septerna.
Septerna’s share price has appreciated 280 % over the preceding twelve months and was trading at $44.50 at the time of reporting, giving the company a market capitalization of approximately $2.11 billion. The filing notes that the reporting persons, including managing members Peter Kolchinsky and Rajeev Shah of RA Capital Management GP, LLC, and partner Jake Simson who sits on Septerna’s board, do not claim beneficial ownership of the sold securities beyond their pecuniary interest.
Analyst coverage updates were also noted: H.C. Wainwright raised its price target to $60, citing progress in the Phase 1 trial of SEP‑479 for hypoparathyroidism; Stifel lifted its target to $49 on the same basis; Guggenheim initially increased its target to $51 after observing promising human half‑life data, but later reduced it to $45 following a competitor’s setback in chronic spontaneous urticaria. H.C. Wainwright maintained a Buy rating and a $40 target after the rival’s Phase 2b results fell short of expectations. Investors with an InvestingPro subscription can access twelve additional exclusive tips on Septerna, including detailed financial health metrics ahead of the company’s earnings release scheduled for August 17, 2026.